DE602005021115D1 - Verfahren und zusammensetzungen zur oralen fts-abgabe - Google Patents

Verfahren und zusammensetzungen zur oralen fts-abgabe

Info

Publication number
DE602005021115D1
DE602005021115D1 DE602005021115T DE602005021115T DE602005021115D1 DE 602005021115 D1 DE602005021115 D1 DE 602005021115D1 DE 602005021115 T DE602005021115 T DE 602005021115T DE 602005021115 T DE602005021115 T DE 602005021115T DE 602005021115 D1 DE602005021115 D1 DE 602005021115D1
Authority
DE
Germany
Prior art keywords
fts
oral
delivery
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021115T
Other languages
English (en)
Inventor
Victor J Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadmon Corp LLC
Original Assignee
Concordia Pharmaceuticals Inc Luxembourg
Concordia Pharmaceuticals Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concordia Pharmaceuticals Inc Luxembourg, Concordia Pharmaceuticals Inc USA filed Critical Concordia Pharmaceuticals Inc Luxembourg
Publication of DE602005021115D1 publication Critical patent/DE602005021115D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005021115T 2004-08-18 2005-08-18 Verfahren und zusammensetzungen zur oralen fts-abgabe Active DE602005021115D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60236104P 2004-08-18 2004-08-18
PCT/US2005/029389 WO2006023639A1 (en) 2004-08-18 2005-08-18 Methods and compositions for oral delivery of fts

Publications (1)

Publication Number Publication Date
DE602005021115D1 true DE602005021115D1 (de) 2010-06-17

Family

ID=35447506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021115T Active DE602005021115D1 (de) 2004-08-18 2005-08-18 Verfahren und zusammensetzungen zur oralen fts-abgabe

Country Status (9)

Country Link
US (4) US8088756B2 (de)
EP (3) EP1778209B8 (de)
AT (2) ATE466574T1 (de)
CA (1) CA2577310C (de)
DE (1) DE602005021115D1 (de)
ES (2) ES2414861T3 (de)
MX (1) MX2007001929A (de)
PL (1) PL1778209T3 (de)
WO (1) WO2006023639A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778209B8 (de) 2004-08-18 2010-06-16 Concordia Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur oralen fts-abgabe
DE602006017728D1 (de) 2005-11-28 2010-12-02 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
WO2007091241A1 (en) * 2006-02-10 2007-08-16 Ramot At Tel Aviv University Ltd. Treatment of ovarian cancer
US20110046223A1 (en) * 2006-06-14 2011-02-24 Ramot At Tel-Aviv University Ltd. Treatment of neurofibromatosis
MX2009006574A (es) 2006-12-19 2009-07-02 Univ Ramot Tratamiento de cancer de pulmon.
JP2013508458A (ja) * 2009-10-26 2013-03-07 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド Ｆｔｓとｈｄａｃ阻害剤との組合せを用いたがん治療
JP6165744B2 (ja) * 2011-10-07 2017-07-19 パイシーズ セラピューティックス エルエルシーＰｉｓｃｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ Ｒａｓアンタゴニストによる悪性および非悪性疾患の治療
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL107587A (en) 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
KR100312454B1 (ko) * 1998-03-27 2001-11-14 김용규 토토마이세틴을 생산하는 스트렙토마이세스 속 미생물 및 그로부터 생산된 토토마이세틴을 유효성분으로 함유하는 면역억제제
JP2003502365A (ja) 1999-06-18 2003-01-21 サイリオス・コーポレイション Ｒａｓアンタゴニストによる非悪性疾患処置
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
AU2001295859A1 (en) 2000-10-04 2002-04-15 Ramot University Authority For Applied Research And Industrial Development Ltd. Isoprenoid-dependent ras anchorage (idra) proteins
US20020169183A1 (en) * 2001-03-08 2002-11-14 Villar Hugo O. Acridines as stimulators for Fas-mediated apoptosis
EP1390472A4 (de) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US20060141472A1 (en) 2003-03-20 2006-06-29 Miikka Vikkula Medical use of ras antagonists for the treatment of capillary malformation
WO2004103352A1 (en) 2003-05-23 2004-12-02 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
AU2004266721A1 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mTOR to prevent a hormonal adaptive response
EP1778209B8 (de) 2004-08-18 2010-06-16 Concordia Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur oralen fts-abgabe
DE602006017728D1 (de) 2005-11-28 2010-12-02 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose

Also Published As

Publication number Publication date
CA2577310C (en) 2011-01-11
US20090226512A1 (en) 2009-09-10
WO2006023639A1 (en) 2006-03-02
EP2301528A1 (de) 2011-03-30
CA2577310A1 (en) 2006-03-02
EP1778209B1 (de) 2010-05-05
ATE535237T1 (de) 2011-12-15
EP2301528B1 (de) 2013-04-03
ES2414861T3 (es) 2013-07-23
EP1778209A1 (de) 2007-05-02
US20160271089A1 (en) 2016-09-22
ES2343737T3 (es) 2010-08-09
US20150191426A1 (en) 2015-07-09
EP1778209B8 (de) 2010-06-16
ATE466574T1 (de) 2010-05-15
MX2007001929A (es) 2007-04-17
PL1778209T3 (pl) 2010-10-29
EP2218451A1 (de) 2010-08-18
EP2218451B1 (de) 2011-11-30
US8088756B2 (en) 2012-01-03
US20120082722A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
HK1102991A1 (en) Pharmaceutical formulation of decitabine
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EP2248519A3 (de) Nichtmukoadhäsive Filmdosierungsformen
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
HRP20140783T1 (hr) Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest
WO2007062186A3 (en) Methods of using small molecule compounds for neuroprotection
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
EA201100305A1 (ru) Лечение респираторных заболеваний
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
ATE302774T1 (de) Arzneimittel enthaltend betamimetika und ein neues anticholinergikum
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2008045559A3 (en) Methods of treating oral mucositis
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
HRP20161197T1 (hr) 24-norudca za liječenje autoimunog hepatitisa
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
WO2007144889A3 (en) Treatment of neurofibromatosis
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
HK1124776A1 (en) Treatment of drug-resistant tumors
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CONCORDIA PHARMACEUTICALS, INC., FORT LAUDERDA, US

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1778209

Country of ref document: EP

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

R081 Change of applicant/patentee

Ref document number: 1778209

Country of ref document: EP

Owner name: KADMON CORPORATION, LLC (N. D. GES.D. STAATES , US

Free format text: FORMER OWNER: CONCORDIA PHARMACEUTICALS, INC., FORT LAUDERDALE, US

Effective date: 20120814

R082 Change of representative

Ref document number: 1778209

Country of ref document: EP

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20120814